Levofloxacin prophylaxis for pediatric leukemia patients: monitoring of outcomes for sustained benefit and consequences.
Andrea L DavisAlexandra M StevensJulienne BrackettLucila MarquezCatherine E FosterAdriana Sarmiento ClementeHannah E SauerGrant T StimesJudith R CampbellPublished in: Antimicrobial stewardship & healthcare epidemiology : ASHE (2024)
Levofloxacin prophylaxis reduces bloodstream infections in neutropenic patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. A retrospective, longitudinal cohort study compares incidence of bacteremia, multidrug-resistant organisms (MDRO), and Clostridioides difficile (CDI) between time periods of levofloxacin prophylaxis implementation. Benefits were sustained without increasing MDRO or CDI.
Keyphrases
- acute myeloid leukemia
- acute lymphoblastic leukemia
- multidrug resistant
- allogeneic hematopoietic stem cell transplantation
- gram negative
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- primary care
- healthcare
- clostridium difficile
- bone marrow
- prognostic factors
- risk factors
- young adults
- patient reported outcomes
- metabolic syndrome
- cross sectional
- multiple myeloma
- hodgkin lymphoma
- patient reported